@article{d04db88e125c400ebf47f48c565f46d3,
title = "Commentary: Early stage epidermal growth factor receptor lung cancer: Skip to the good stuff?",
author = "Stiles, {Brendon M.}",
note = "Funding Information: Disclosures: The Dr Stiles reports consulting/speaker fees from AstraZeneca, Pfizer, Bristol Myers Squibb, Genentech, Galvanize Therapeutics, and Flame Biosciences; grant support and trial funding from Bristol Myers Squibb; and is a board member of the Lung Cancer Research Foundation. His spouse receives salary/stock from Xalud Therapeutics, Pfizer, and PPD. Funding Information: Disclosures: The Dr Stiles reports consulting/speaker fees from AstraZeneca, Pfizer, Bristol Myers Squibb, Genentech, Galvanize Therapeutics, and Flame Biosciences; grant support and trial funding from Bristol Myers Squibb; and is a board member of the Lung Cancer Research Foundation. His spouse receives salary/stock from Xalud Therapeutics, Pfizer, and PPD. ",
year = "2022",
month = nov,
doi = "10.1016/j.jtcvs.2022.02.001",
language = "English (US)",
volume = "164",
pages = "1316--1317",
journal = "Journal of Thoracic and Cardiovascular Surgery",
issn = "0022-5223",
publisher = "Mosby Inc.",
number = "5",
}
